Premium
Pediatric non‐Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand
Author(s) -
Choeyprasert Worawut,
Anurathapan Usanarat,
Pakakasama Samart,
Sirachainan gnuch,
Songdej Duantida,
Lertthammakiat Surapong,
Hongeng Suradej
Publication year - 2019
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.13739
Subject(s) - medicine , lymphoma , lymphoblastic lymphoma , disease , epidemiology , chemotherapy , stage (stratigraphy) , peripheral t cell lymphoma , oncology , immunology , t cell , paleontology , immune system , biology
Background In the modern era of chemotherapy, the outcome of pediatric non‐Hodgkin lymphoma ( NHL ) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries. Methods Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. Results In total, 114 patients were enrolled; they were predominantly male (65.8%) and had advanced disease (stage III , IV ; 71.9%). Of these, 22.8% had Burkitt lymphoma, 20.2% had diffuse large B‐cell lymphoma, 21.1% had lymphoblastic lymphoma, 20.2% had large cell lymphoma, and 15.8% had peripheral T‐cell lymphoma. Twenty‐nine patients died, especially of uncontrolled disease (62.1%) and infection (20.7%). During a median follow up of 78.4 months, Kaplan–Meier 5 year event‐free and overall survival rates were 71.5% ± 4.3% and 74.8% ± 4.1%, respectively, regardless of subtype. B symptoms (i.e. systemic symptoms of fever, night sweats, and weight loss that can be associated with both Hodgkin's lymphoma and non‐Hodgkin's lymphoma) and advanced disease had a significant negative impact on 5 year survival. No other prognostic factor was found, but survival tended to have a negative correlation with age. Conclusions Pediatric NHL is aggressive, with a high prevalence of peripheral T‐cell lymphoma. The present treatment stratification seems to be effective compared with that used in developed countries.